Safety and efficacy of a saquinavir-containing antiretroviral regimen in previously ART-naïve or pretreated but protease inhibitor-naïve HIV-positive patients

Infection

Volumn 38, Issue 2, 2010, Pages 108-116

  Knechten, H ^a   Stephan, C ^b   Mosthaf, F A ^c   Jaeger, H ^d   Lutz, T ^e   Cargnico, A ^f   Stoehr, A ^g   Koeppe, S ^h   Mayr, C ⁱ   Schewe, K ^j   Wolf, E ^k   Wellmann, E ^l   Tappe, A ^l  

^a Praxen Zentrum Blondelstrasse   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c Practice Drs FA Mosthaf/M Procaccianti/K Zutavern Bechtold   (Germany)

^d Diagnostik München   (Germany)

^e Infektiologikum Frankfurt ^*  (Germany)

^f Practice Dupke/Carganico/Baumgarten   (Germany)

^g Institute for Interdisciplinary Medicine   (Germany)

^h Practice Drs S Koeppe/P Kreckel   (Germany)

ⁱ Drs C Mayr/PD W Schmidt   (Germany)

^j Institute for Infectious Diseases   (Germany)

^k MUC Research GmbH and MVZ Karlsplatz   (Germany)

^l ROCHE INNOVATION CENTER MUNICH   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; EFAVIRENZ; EMTRICITABINE; LOPINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CAUCASIAN; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GENE DOSAGE; HEPATITIS B; HEPATITIS C; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; MULTICENTER STUDY; SIDE EFFECT; VIRUS LOAD;

ADMINISTRATION, ORAL; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LIPIDS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; RNA, VIRAL; SAQUINAVIR; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77953232859     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-009-9249-x     Document Type: Article

References (18)

1. A. Mocroft R. Brettle O. Kirk A. Blaxhult J.M. Parkin F. Antunes P. Francioli A. D'Arminio Monforte Z. Fox J.D. Lundgren EuroSIDA study group 2002 Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study AIDS 16 1663 1671 10.1097/00002030-200208160-00012 1:STN:280:DC%2BD38vltVSkug%3D%3D 12172088 (Pubitemid 34921112)
2. S. Hariri M.T. McKenna 2007 Epidemiology of human immunodeficiency virus in the United States Clin Microbiol Rev 20 478 488 10.1128/CMR.00006-07 17630336 (Pubitemid 47175015)
3. S.M. Hammer J.J. Eron Jr P. Reiss R.T. Schooley M.A. Thompson S. Walmsley P. Cahn M.A. Fischl J.M. Gatell M.S. Hirsch D.M. Jacobsen J.S. Montaner D.D. Richman P.G. Yeni P.A. Volberding 2008 International AIDS Society-USA: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel JAMA 300 555 570 10.1001/jama.300.5.555 1:CAS:528:DC%2BD1cXps1ylsbc%3D 18677028
4. B. Bittner M. Riek B. Holmes S. Grange 2005 Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers Antivir Ther 10 803 810 1:CAS:528:DC%2BD28Xht1Q%3D 16312177
5. D.R. Bangsberg F.M. Hecht E.D. Charlebois A.R. Zolopa M. Holodniy L. Sheiner J.D. Bamberger M.A. Chesney A. Moss 2000 Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population AIDS 14 357 366 10.1097/00002030-200003100-00008 1:CAS:528: DC%2BD3cXis1egu7s%3D 10770537 (Pubitemid 30182431)
6. D.L. Paterson S. Swindells J. Mohr M. Brester E.N. Vergis C. Squier M.M. Wagener N. Singh 2000 Adherence to protease inhibitor therapy and outcomes in patients with HIV infection Ann Intern Med 133 21 30 1:STN:280: DC%2BD3czit1altA%3D%3D 10877736
7. E.M. Gardner S. Sharma G. Peng K.H. Hullsiek W.J. Burman R.D. Macarthur M. Chesney E.E. Telzak G. Friedland S.B. Mannheimer 2008 Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance AIDS 22 75 82 10.1097/QAD.0b013e3282f366ff 1:CAS:528: DC%2BD2sXhsVequrbM 18090394 (Pubitemid 350294880)
8. V.D. Lima R. Harrigan D.R. Bangsberg R.S. Hogg R. Gross B. Yip J.S. Montaner 2009 The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time J Acquir Immune Defic Syndr 50 529 536 10.1097/QAI.0b013e31819675e9 1:CAS:528:DC%2BD1MXjtlOht78%3D 19223785
9. U.B. Dragsted J. Gerstoft M. Youle Z. Fox M. Losso J. Benetucci D.T. Jayaweera A. Rieger J.N. Bruun A. Castagna B. Gazzard S. Walmsley A. Hill J.D. Lundgren MaxCmin2 Trial Group 2005 A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial Antivir Ther 10 735 743 1:CAS:528:DC%2BD2MXhtF2ntbbI 16218173
10. J. Ananworanich A. Gayet-Ageron K. Ruxrungtham P. Chetchotisakd W. Prasithsirikul S. Kiertiburanakul W. Munsakul P. Raksakulkarn S. Tansuphasawadikul M. LeBraz T. Jupimai S. Ubolyam M. Schutz B. Hirschel Staccato Thailand Study Group 2008 Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir Antivir Ther 13 375 380 1:CAS:528:DC%2BD1cXotVagsLo%3D 18572750
11. S. Walmsley A. Avihingsanon J. Slim D.J. Ward K. Ruxrungtham J. Brunetta U.F. Bredeek D. Jayaweera C.J. Guittari P. Larson M. Schutz F. Raffi 2009 Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults J Acquir Immune Defic Syndr. 50 367 374 10.1097/QAI.0b013e318198a815 19214123
12. U.B. Dragsted J. Gerstoft C. Pedersen B. Peters A. Duran N. Obel A. Castagna P. Cahn N. Clumeck J.N. Bruun J. Benetucci A. Hill I. Cassetti P. Vernazza M. Youle Z. Fox J.D. Lundgren MaxCmin1 Trial Group 2003 Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial J Infect Dis 188 635 642 10.1086/377288 1:CAS:528:DC%2BD3sXnvFyisbs%3D 12934178 (Pubitemid 37115175)
13. J.L. Casado R. Sabido M.J. Perez-Elías A. Antela J. Oliva F. Dronda B. Mejía J. Fortún 1999 Percentage of adherence correlates with the risk of protease inhibitor (PI) treatment failure in HIV-infected patients Antivir Ther 4 157 161 1:CAS:528:DyaK1MXnsFGmt70%3D 12731755
14. P. García de Olalla H. Knobel A. Carmona A. Guelar J.L. López-Colomés J.A. Caylà 2002 Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients J Acquir Immune Defic Syndr 30 105 110 10.1097/00126334-200205010-00014 12048370 (Pubitemid 34506694)
15. V. Le Moing G. Chêne M.P. Carrieri A. Alioum F. Brun-Vézinet L. Piroth J.P. Cassuto J.P. Moatti F. Raffi C. Leport Aproco Study Group 2002 Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen AIDS 16 21 29 10.1097/00002030-200201040- 00004 11741159 (Pubitemid 34062178)
16. J.M. Raboud M. Harris S. Rae J.S. Montaner 2002 Impact of adherence on duration of virological suppression among patients receiving combination antiretroviral therapy HIV Med 3 118 124 10.1046/j.1468-1293.2002.00109.x 1:STN:280:DC%2BD38zhs1SisQ%3D%3D 12010358 (Pubitemid 34567582)
17. R.S. Autar M. Boffito E. Hassink F.W. Wit J. Ananworanich U. Siangphoe A. Pozniak D.A. Cooper P. Phanuphak J.M. Lange K. Ruxrungtham D.M. Burger 2005 Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients J Antimicrob Chemother 56 908 913 10.1093/jac/dki354 1:CAS:528:DC%2BD2MXhtFCjtLfI 16204340 (Pubitemid 41631916)
18. L. Calza R. Manfredi F. Chiodo 2004 Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients J Antimicrob Chemother 53 10 14 10.1093/jac/dkh013 1:CAS:528:DC%2BD3sXhtVShsb3M 14645323 (Pubitemid 38072177)